Improved outcomes of allogeneic hematopoietic stem cell transplantation including haploidentical transplantation for childhood myelodysplastic syndrome


This retrospective study aimed to investigate the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for childhood myelodysplastic syndrome (MDS). Thirty-six patients (low-grade MDS, 24; advanced MDS, 12) received HSCT at the Asan Medical Center over two decades (early period, 1997–2007; recent period, 2008–2017). The transplantation outcomes were analyzed according to disease status, conditioning regimen, various donor types, and period of HSCT. During a median follow-up of 5.6 (range, 1.4–21.1) years, the probability of overall survival (OS) and failure-free survival was 77% and 69%, respectively. The cumulative incidence of transplantation-related mortality (TRM) was 12%. Significantly reduced TRM and improved OS were observed in patients who received HSCT during the recent period vs. the early period (TRM, 4% vs. 30%, P = 0.021; OS, 87% vs. 50%, P = 0.006). Comparable outcomes were observed for HSCT from haploidentical family donors vs. HLA-identical donors (TRM, 10% vs. 14%, P= 0.837; OS, 86% vs. 79%, P = 0.625). This study identified the improved outcomes of allogeneic HSCT for childhood MDS over time, in addition, the feasible outcomes of haploidentical HSCT suggested its use as an attractive alternative in the future procedures.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. 1.

    Hasle H, Wadsworth LD, Massing BG, McBride M, Schultz KR. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol. 1999;106:1027–32.

    CAS  Article  Google Scholar 

  2. 2.

    Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematol Am Soc Hematol Educ Program. 2011;2011:84–9.

    Article  Google Scholar 

  3. 3.

    Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277–82.

    CAS  Article  Google Scholar 

  4. 4.

    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissue, 4th ed. Lyon, France: IARC; 2008.

  5. 5.

    Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.

    CAS  Article  Google Scholar 

  6. 6.

    Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol Am Soc Hematol Educ Program. 2016;2016:598–604.

    Article  Google Scholar 

  7. 7.

    Inagaki J, Fukano R, Kurauchi K, Noguchi M, Tanioka S, Okamura J. Hematopoietic stem cell transplantation in children with refractory cytopenia of childhood: single-center experience using high-dose cytarabine containing myeloablative and aplastic anemia oriented reduced-intensity conditioning regimens. Biol Blood Marrow Transpl. 2015;21:565–9.

    CAS  Article  Google Scholar 

  8. 8.

    Hasegawa D, Chen X, Hirabayashi S, Ishida Y, Watanabe S, Zaike Y, et al. Clinical characteristics and treatment outcome in 65 cases with refractory cytopenia of childhood defined according to the WHO 2008 classification. Br J Haematol. 2014;166:758–66.

    CAS  Article  Google Scholar 

  9. 9.

    Andolina JR, Kletzel M, Tse WT, Jacobsohn DA, Duerst RE, Schneiderman J, et al. Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: improved outcomes for de novo disease. Pediatr Transpl. 2011;15:334–43.

    Article  Google Scholar 

  10. 10.

    Strahm B, Locatelli F, Bader P, Ehlert K, Kremens B, Zintl F, et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transpl. 2007;40:329–33.

    CAS  Article  Google Scholar 

  11. 11.

    Yusuf U, Frangoul HA, Gooley TA, Woolfrey AE, Carpenter PA, Andrews RG, et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transpl. 2004;33:805–14.

    CAS  Article  Google Scholar 

  12. 12.

    Kardos G, Baumann I, Passmore SJ, Locatelli F, Hasle H, Schultz KR, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003;102:1997–2003.

    CAS  Article  Google Scholar 

  13. 13.

    Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia 2001;15:1713–20.

    CAS  Article  Google Scholar 

  14. 14.

    Woods WG, Barnard DR, Alonzo TA, Buckley JD, Kobrinsky N, Arthur DC, et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children’s Cancer Group. J Clin Oncol. 2002;20:434–40.

    PubMed  Google Scholar 

  15. 15.

    Galaverna F, Ruggeri A, Locatelli F. Myelodysplastic syndromes in children. Curr Opin Oncol. 2018;30:402–8.

    PubMed  Google Scholar 

  16. 16.

    Locatelli F, Strahm B. How I treat myelodysplastic syndromes of childhood. Blood. 2018;131:1406–14.

    CAS  Article  Google Scholar 

  17. 17.

    Gohring G, Michalova K, Beverloo HB, Betts D, Harbott J, Haas OA, et al. Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood. 2010;116:3766–9.

    Article  Google Scholar 

  18. 18.

    Moriwaki K, Manabe A, Taketani T, Kikuchi A, Nakahata T, Hayashi Y. Cytogenetics and clinical features of pediatric myelodysplastic syndrome in Japan. Int J Hematol. 2014;100:478–84.

    Article  Google Scholar 

  19. 19.

    Hofmann I. Pediatric myelodysplastic syndromes. J Hematopathol. 2015;8:127–41.

    Article  Google Scholar 

  20. 20.

    Im HJ, Koh KN, Seo JJ. Recent advances in haploidentical hematopoietic stem cell transplantation using ex vivo T cell-depleted graft in children and adolescents. Blood Res. 2016;51:8–16.

    CAS  Article  Google Scholar 

  21. 21.

    Im HJ, Koh KN, Suh JK, Lee SW, Choi ES, Jang S, et al. Haploidentical HCT using an alphabeta T-cell-depleted graft with targeted alphabeta(+) cells by add-back after a reduced intensity preparative regimen containing low-dose TBI. Bone Marrow Transpl. 2016;51:1217–22.

    CAS  Article  Google Scholar 

  22. 22.

    Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus conference on Acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.

    CAS  Google Scholar 

  23. 23.

    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945–56.

    Article  Google Scholar 

  24. 24.

    Locatelli F, Lucarelli B, Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Exp Opin Pharmacother. 2014;15:23–36.

    CAS  Article  Google Scholar 

  25. 25.

    Maruyama K, Aotsuka N, Kumano Y, Sato N, Kawashima N, Onda Y, et al. Immune-mediated hematopoietic failure after allogeneic hematopoietic stem cell transplantation: a common cause of late graft failure in patients with complete donor chimerism. Biol Blood Marrow Transpl. 2018;24:43–9.

    CAS  Article  Google Scholar 

  26. 26.

    Munoz A, Diaz-Heredia C, Badell I, Bureo E, Gomez P, Martinez A, et al. Allogeneic stem cell transplantation for myelodysplastic syndromes in children: a report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Pediatr Hematol Oncol. 2009;26:345–55.

    Article  Google Scholar 

  27. 27.

    Kook H, Kim CJ, Yoon WS, Ryu NE, Chung KJ, Hwang TJ. A clinical study of pediatric myelodysplastic syndrome:application of international prognostic scoring system and the review of the Korean literature. J Korean Cancer Assoc. 2000;32:178–90.

    Google Scholar 

  28. 28.

    Lee J, Kim SY, Cho B, Jang PS, Chung NK, Kim HK. Short-term results of hematopoietic stem cell transplantation for children with myelodysplastic syndrome. J Korean Pediatr Soc. 2002;45:370–5.

    Google Scholar 

  29. 29.

    Basquiera AL, Pizzi S, Correas AG, Longo PG, Goldman WC, Prates MV, et al. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina. Pediatr Blood Cancer. 2015;62:153–7.

    Article  Google Scholar 

  30. 30.

    Strahm B, Nollke P, Zecca M, Korthof ET, Bierings M, Furlan I, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011;25:455–62.

    CAS  Article  Google Scholar 

  31. 31.

    Webb DK, Passmore SJ, Hann IM, Harrison G, Wheatley K, Chessells JM. Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990–99. Br J Haematol. 2002;117:33–9.

    Article  Google Scholar 

  32. 32.

    Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12:1214–21.

    CAS  Article  Google Scholar 

  33. 33.

    Rocha V, Kabbara N, Ionescu I, Ruggeri A, Purtill D, Gluckman E. Pediatric related and unrelated cord blood transplantation for malignant diseases. Bone Marrow Transpl. 2009;44:653–9.

    CAS  Article  Google Scholar 

  34. 34.

    Hasle H, Baumann I, Bergstrasser E, Fenu S, Fischer A, Kardos G, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia. 2004;18:2008–14.

    CAS  Article  Google Scholar 

  35. 35.

    Trobaugh-Lotrario AD, Kletzel M, Quinones RR, McGavran L, Proytcheva MA, Hunger SP, et al. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT). Bone Marrow Transpl. 2005;35:143–9.

    CAS  Article  Google Scholar 

  36. 36.

    Hasle H. Myelodysplastic syndromes in childhood-classification, epidemiology, and treatment. Leuk Lymphoma. 1994;13:11–26.

    CAS  Article  Google Scholar 

  37. 37.

    Parikh SH, Mendizabal A, Martin PL, Prasad VK, Szabolcs P, Driscoll TA, et al. Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. Biol Blood Marrow Transpl. 2009;15:948–55.

    Article  Google Scholar 

  38. 38.

    Woodard P, Carpenter PA, Davies SM, Gross TG, He W, Zhang MJ, et al. Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. Biol Blood Marrow Transpl. 2011;17:723–8.

    Article  Google Scholar 

Download references


This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI10C2020).

Author information



Corresponding author

Correspondence to Ho Joon Im.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Yoo, J.W., Im, H.J., Kim, H. et al. Improved outcomes of allogeneic hematopoietic stem cell transplantation including haploidentical transplantation for childhood myelodysplastic syndrome. Bone Marrow Transplant 55, 1595–1603 (2020).

Download citation


Quick links